The CEA vaccine, GI-6207, was investigated in a phase 1 trial that enrolled 25 patients with metastatic CEA-expressing carcinomas and included one patient with MTC (71). The gene discussed is CEACAM5; the disease is medullary thyroid gland carcinoma.